Eli Lilly has ended its collaboration with Foghorn Therapeutics after a cancer drug disappointed in testing, BioPharma Dive reports. The split is one of several items in the publication's latest biotech roundup, which also flags Wave's FDA-approved plans, an expanded partnership between Teva and Samsung Bioepis, and a $251 million funding round for space biotech Varda.
The roundup gives no further detail on the Foghorn drug's performance or on Wave's regulatory plans. It does say that Teva and Samsung Bioepis broadened their existing partnership and that Varda raised $251 million.
Because the article is a single news roundup, there are no conflicting sources to compare; the facts are presented as reported by BioPharma Dive.